Current Location: HOME >> Enterprise Certification
Contact information
| Country: | China |
|---|---|
| Tel: | 027-65026759 |
| Mobile: | 13135669090 |
| E-mail: | sales1@hybio.com.cn |
| QQ: | 2967741380 |
| Skype: | Chat Now! |
| Address: | 9 Linkong West St., 430301 |
Company Profile
-
Enterprise Basic Information
Enterprise Certification
 |
|
| Type of Enterprise: | Private |
| Legal Representative: | Mr. Yangming Tang |
| Registered Capital: | RMB 350 Million |
| Founded Date: | 2014-01-16 |
| Registered Address: | 9 Linkong West St., Wuhan, Hubei, 430301, China |
| Term of Validity: | 2014-01-16—2099-12-31 |
| Business Scope: | Drug production; Import and export of drugs; Import and export of goods; Wholesale of pharmaceuticals; Retail of pharmaceuticals (projects that require approval by law and can only be carried out after approval by relevant departments, with specific business projects subject to approval documents or licenses from relevant departments) General projects: research and development of biochemical product technology; Asset management services for self owned fund investments; Manufacturing of specialized chemical products (excluding hazardous chemicals); Sales of specialized chemical products (excluding hazardous chemicals); Housing rental; Non residential real estate leasing; Manufacturing of basic chemical raw materials (excluding the manufacturing of licensed chemicals such as hazardous chemicals); Medical research and experimental development; Manufacturing of medical packaging materials; Technical services, technology development, technology consulting, technology exchange, technology transfer, and technology promotion (except for projects that require approval according to law, business activities can be carried out independently with a business license in accordance with the law) |
| Staff number: | 100-500 People |
| Number of R & D department: | 20-50 |
| Annual turnover： | RMB Below RMB 1 million |
| Main consumer market： | Pharmaceutical factory Material factory Medical materials factory trading company hospital |
| Main marketing location： | United States Japan India South Korea Germany |
| Main product or service： | Semaglutide, Tirzepatide, Liraglutide, CMO, CDMO |
Manufacturer
| Marketing : | Hybio Pharmaceutical (Wuhan) Co., Ltd. |
| Address: | 9 Linkong West St., Wuhan, Hubei, 430301, China |
| Area: | 360 Acres |
| Pictures of scenes: | |
|
|
|
| Marketing : | Hybio Pharmaceutical (Wuhan) Co., Ltd. |
| Address: | 9 Linkong West St., Wuhan, Hubei, 430301, China |
| Area: | 360 Acres |
| Equipment: | CSbio |
| Pictures of scenes: | |
|
|
| Brief description : | Quality is not just a component of our operational framework; it is the backbone of our manufacturing ethos. Our production sites for Active Pharmaceutical Ingredients (API) and Finished Dosage Forms (FDF) have successfully passed stringent inspections in critical markets, including China, the US, Europe, and South Korea. This global compliance underscores our commitment to adhering to international quality standards, ensuring that our products are synonymous with excellence. Our "quality first |
| Quality inspection equipment: | IC / LC-MS |
|
|
| Certificate of accreditation: | Manufacturing License |
|
|
| Brief description : | Our factory workshops are located in Wuhan City, Hubei Province, it is designed and built according to cGMP standards and introduces internationally leading production technology and advanced equipment. |
| Pictures of scenes: | |
|
|
|
| Staff composition for example: | In the evolving world of peptide pharmaceuticals, Hybio Pharmaceutical actively engages with a profound commitment to research and development (R&D) and an unwavering dedication to quality. Our journey is fueled by a passion for innovation, a pursuit that has led us to invest significantly in our R&D efforts, reflecting a substantial 29.41% of our revenue back into research in Q1-3 2023 alone. This investment is a testament to our resolve to lead and redefine the industry standards. |
| Professional skills: | At the heart of our R&D prowess is our team, a diverse group of over 203 researchers, who constitute 20.80% of our workforce. This talented pool of individuals is not just a number; it represents a melting pot of ideas, expertise, and ambition. Collaborating with leading domestic and international research institutions, we've expanded our horizons, bringing on board more than 20 distinguished technical consultants who share our vision for the future of healthcare. Our commitment to innovation i |
| Pictures of scenes: | |